Sangamo Therapeutics, Inc., which operates in the biotechnology industry developing gene therapies, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code on June 23, 2026. On August 25, 2026, the Company entered into an Asset Purchase Agreement with PTC Therapeutics, Inc., to sell assets primarily related to ST-920, a gene therapy candidate for Fabry disease. The transaction includes $111 million in cash consideration and up to $100 million in contingent milestone payments upon FDA approval of a biologics license application. The deal is subject to Bankruptcy Court approval, with a hearing scheduled for September 10, 2026.

Sangamo Therapeutics announced the conclusion of a court-supervised Section 363 auction under its Chapter 11 bankruptcy case, selecting winning bids from PTC Therapeutics and Eli Lilly. The transactions yield approximately $163.55 million in cash consideration at closing plus potential milestone payments up to $100 million. PTC will acquire the Fabry disease program isaralgagene civaparvovec for $111 million upfront and up to $100 million in milestones, while Lilly will purchase capsid delivery, zinc finger, MINT platforms, and a prion disease program for $50 million. Additional assets including tools and equipment were sold for $2.55 million. The sales remain subject to Bankruptcy Court approval and Hart-Scott-Rodino clearance, with expected closings in September 2026 or later. Sangamo Therapeutics is a genomic medicine company developing therapies for rare diseases.

Sangamo Therapeutics, Inc., which filed for Chapter 11 bankruptcy protection on June 23, 2026, has filed its monthly operating report with the U.S. Bankruptcy Court for the period ending June 30, 2026. The company reported a cash balance of $14.4 million at month-end and total assets of $153.1 million against liabilities of $89.2 million. During the reporting period, Sangamo generated $109,000 in gross income while incurring $3.8 million in net losses, primarily driven by reorganization items. The company maintains 73 full-time employees and continues to trade on the OTC Markets under the symbol SGMOQ following its delisting from Nasdaq. Sangamo Therapeutics operates as a biotechnology company focused on developing gene editing therapies.

On July 14, 2026, the Nasdaq Hearings Panel denied Sangamo Therapeutics' request to continue its listing on Nasdaq, following a previous suspension on May 5, 2026. The company does not intend to request further review and expects its common stock to be deregistered. Additionally, the U.S. Bankruptcy Court for the District of Delaware entered an order approving bidding procedures for the sale of all or substantially all of the company's assets. Key dates include a bid deadline of August 4, 2026, a potential auction on August 10, 2026, and a sale hearing on August 20, 2026. The company is currently operating as a debtor-in-possession under Chapter 11 bankruptcy. Sangamo Therapeutics is a biotechnology company that develops therapeutic products for the treatment of diseases.

Sangamo Therapeutics, Inc. filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code (Case No. 26-10989). Following the bankruptcy filing, the company's common stock began trading on the OTCID Basic Market under the symbol "SGMOQ" on June 24, 2026. Additionally, the company terminated the engagement of Ernst & Young LLP as its independent registered public accounting firm on June 25, 2026. Sangamo Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for genetic diseases.

Sangamo Therapeutics filed an amendment to a previous 8-K to include Asset Purchase Agreements dated June 22, 2026, with Eli Lilly and Company and Astellas Gene Therapies, Inc. The filing also references a Nasdaq delisting notification received April 28, 2026, due to minimum bid price non-compliance, which resulted in the common stock trading on the OTCQB Venture Market starting May 5, 2026. The company is a biotechnology company that develops therapeutic products for the treatment of genetic diseases.